• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

FDA-TRACK

The list below provides information on FDA’s performance measures and projects as aligned to FDA strategic priorities and program offices. This list enables you to view charts of performance data and progress on important projects and programs.

To view completed FDA-TRACK performance measures and projects view the Archive Index

Filter








Results

Number of results: 24

ItemProgramOfficeStrategic PlanStrategic Goal/Area
1Percentage of correspondence responded to within the monthCVMOffice of the Center DirectorN/AN/A
2Total number of correspondence received within the monthCVMOffice of the Center DirectorN/AN/A
3Total number of correspondence responded to within the monthCVMOffice of the Center DirectorN/AN/A
4Percentage of international meeting requests received by CVM from others and that are held at CVM on a monthly basisCVMOffice of the Center DirectorN/AN/A
5Percentage of meeting requests received by CVM from others and that are held/hosted by others on a monthly basisCVMOffice of the Center DirectorN/AN/A
6Percentage of bilateral meetings conducted in the quarterCVMOffice of the Center DirectorN/AN/A
7Percentage of trilateral meetings conducted in the quarterCVMOffice of the Center DirectorN/AN/A
8Percentage of WTO SPS notifications commented on within 15 days of date assignedCVMOffice of the Center DirectorN/AN/A
9Percentage of PMAPs established for new CVM employees completed on-time, within 30 days of arrival, during the monthCVMOffice of ManagementN/AN/A
10Percentage of designation submissions reviewed and acted on within 100 daysCVMOffice of Minor Use and Minor Species Animal Drug DevelopmentN/AN/A
11Percentage of INAD study submissions reviewed within the month that were acted on within 180 days after the submission dateCVMOffice of New Animal Drug EvaluationN/AN/A
12Percentage of INAD submissions consisting of protocols without substantial data reviewed and acted on within the month where the sponsor was notified of the Agency's decision on or before day 50CVMOffice of New Animal Drug EvaluationN/AN/A
13Percentage of manufacturing supplemental new animal drug applications and reactivations of such supplemental applications reviewed within the month that were acted on within 120 days after the submission dateCVMOffice of New Animal Drug EvaluationN/AN/A
14Percentage of non-administrative original ANADAs and reactivations of such applications completed on timeCVMOffice of New Animal Drug EvaluationN/AN/A
15Percentage of manufacturing supplemental ANADAs and reactivations of such supplemental applications completed on timeCVMOffice of New Animal Drug EvaluationN/AN/A
16Percentage of JINAD study submissions completed on timeCVMOffice of New Animal Drug EvaluationN/AN/A
17Percentage of JINAD submissions consisting of protocols without substanial data completed on timeCVMOffice of New Animal Drug EvaluationN/AN/A
18Percentage of administrative ANADAs (ANADAs submitted after all scientific decisions have been made in the JINAD process) completed on timeCVMOffice of New Animal Drug EvaluationN/AN/A
19Linkages between Gene and Protein Expression and Chemical Exposures Measures - Determine the impact of canine MDR-1 mutations on therapeutic effectiveness and adverse reactions to veterinary drugsCVMOffice of ResearchN/AN/A
20Updating Obsolete Regulatory Residue Methods ProjectCVMOffice of ResearchN/AN/A
21Percentage of electronic ADE submissionsCVMOffice of Surveillance and ComplianceN/AN/A
22Number of warning letters received, completed and pendingCVMOffice of Surveillance and ComplianceN/AN/A
23Average number of business days for CVM to complete the review of warning letters from ORA districts and number of OSC staff reviewing warning letters during the monthCVMOffice of Surveillance and ComplianceN/AN/A
24Development of XML Files for Releasable CVM ADE DataCVMOffice of Surveillance and ComplianceN/AN/A

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information in the Archive Index may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.